

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

HH [Human lymphoma]

RRID:CVCL_1280

Type: Cell Line

Proper Citation

RRID:CVCL_1280

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1280

Proper Citation: RRID:CVCL_1280

Description: Cell line HH [Human lymphoma] is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Primary cutaneous T-cell non-Hodgkin lymphoma

Defining Citation: [PMID:1879969](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:25355872](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HH [Human lymphoma]

Cross References: CLO:CLO_0003744, EFO:EFO_0002194, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-2105, BCRC:60248, BioSample:SAMN03472543, BioSample:SAMN10987897, cancercellines:CVCL_1280, Cell_Model_Passport:SIDM00671, ChEMBL-Cells:ChEMBL3308142, ChEMBL-Targets:ChEMBL2366310, Cosmic:687843, Cosmic:907056, Cosmic:1551452, Cosmic:2153071, Cosmic:2402471, Cosmic-CLP:907056, DepMap:ACH-000061, DSMZ:ACC-707, DSMZCellDive:ACC-707,

EGA:EGAS00001000978, GDSC:907056, GEO:GSM887082, GEO:GSM888152, GEO:GSM1669882, IARC_TP53:21371, IGRhCellID:HH, LiGeA:CCLE_426, LINCS_LDP:LCL-1141, PharmacDB:HH_544_2019, PRIDE:PXD030304, Progenetix:CVCL_1280, PubChem_Cell_line:CVCL_1280, Wikidata:Q54887334

ID: CVCL_1280

Record Creation Time: 20220427T220428+0000

Record Last Update: 20260829T233856+0000

Ratings and Alerts

No rating or validation information has been found for HH [Human lymphoma].

No alerts have been found for HH [Human lymphoma].

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Ianevski A, et al. (2026) Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery. Cancer research, 86(2), 295.

Rink JS, et al. (2024) Encapsulation and Delivery of the Kinase Inhibitor PIK-75 by Organic Core High-Density Lipoprotein-Like Nanoparticles Targeting Scavenger Receptor Class B Type 1. ACS applied materials & interfaces.

Coats JT, et al. (2024) Elraglusib Induces Cytotoxicity via Direct Microtubule Destabilization Independently of GSK3 Inhibition. Cancer research communications, 4(11), 3013.

Ward GA, et al. (2024) Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma. Cancer research communications, 4(6), 1441.

Gro?? E, et al. (2023) SAM-Competitive EZH2-Inhibitors Induce Platinum Resistance by EZH2-Independent Induction of ABC-Transporters. Cancers, 15(11).

Merk-Ahmad K, et al. (2023) The RHOA Mutation G17V Does Not Lead to Increased Migration of Human Malignant T Cells but Is Associated with Matrix Remodelling. Cancers, 15(12).

Schleser SW, et al. (2023) Palladium and Platinum Complexes of the Antimetabolite Fludarabine with Vastly Enhanced Selectivity for Tumour over Non-Malignant Cells. *Molecules* (Basel, Switzerland), 28(13).

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Andrews JM, et al. (2021) Loss of synergistic transcriptional feedback loops drives diverse B-cell cancers. *EBioMedicine*, 71, 103559.

Khan H, et al. (2019) Metabolic Rewiring in Response to Biguanides Is Mediated by mROS/HIF-1a in Malignant Lymphocytes. *Cell reports*, 29(10), 3009.

Andrews JM, et al. (2019) Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma. *EBioMedicine*, 46, 170.

Yamagishi M, et al. (2019) Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas. *Cell reports*, 29(8), 2321.